Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AdverseEvent Clear all
Completed No phase listed Observational

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

NCT05054218
View directory record Official record
Conditions
Covid19, SARS-CoV2 Infection
Interventions
mRNA-1273
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 22, 2026, 10:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Culturally Adapted Parenting Intervention for Spanish-Speaking Parents in Improving Outcomes of Younger Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Survivors at Risk for Late Neurocognitive Effects

NCT02559557
View directory record Official record
Conditions
Cancer Survivor, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Cognitive Side Effects of Cancer Therapy
Interventions
Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 10:37 PM EDT
Active, not recruiting Not applicable Interventional

Population Health Approach to Optimizing Medications in Older Adults

NCT06110156
View directory record Official record
Conditions
Medication Adverse Effects, Older Adults (65 Years and Older), Polypharmacy, Polypharmacy Patients, Deprescribing
Interventions
Patient-tailored deprescribing assessment and intervention
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 22, 2026, 10:37 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

NCT06699056
View directory record Official record
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 22, 2026, 10:37 PM EDT
Terminated Phase 1 Interventional

Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer

NCT01790035
View directory record Official record
Conditions
Gastrointestinal Neoplasms
Interventions
LGG, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 22, 2026, 10:37 PM EDT
Withdrawn Phase 2 Interventional

Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk

NCT04473924
View directory record Official record
Conditions
Infection, Transplant;Failure,Kidney
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 22, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional Results available

STOP Heart Disease in Breast Cancer Survivors Trial

NCT02674204
View directory record Official record
Conditions
Breast Cancer, Heart Disease, Cardiotoxicity, Myocardial Dysfunction
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 22, 2026, 10:37 PM EDT
Active, not recruiting Not applicable Interventional

Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial

NCT07442578
View directory record Official record
Conditions
Childhood Cancer Survivors, Cardiotoxicity, Cardiovascular Diseases, Anthracycline-induced Cardiotoxicity
Interventions
HIIT Exercise Program, MICT Exercise Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 22, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

NCT06844669
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2+ Breast Cancer
Interventions
Carvedilol, Empagliflozin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 22, 2026, 10:37 PM EDT
Enrolling by invitation Not applicable Interventional

Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Pain Following Thoracic Trauma

NCT06069154
View directory record Official record
Conditions
Rib Fracture, Rib Fracture Multiple
Interventions
Cryoneurolysis, Local anesthetic peripheral nerve block, Sham Cryoneurolysis, Sham peripheral nerve block
Device · Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
La Jolla, California • Bethesda, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 10:37 PM EDT
Recruiting Phase 3 Interventional

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant, Placebo for Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 17 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
32
States / cities
Huntsville, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 10:37 PM EDT
Recruiting Phase 2 Interventional

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

NCT06470971
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions
Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Siltuximab
Biological · Procedure · Other
Lead sponsor
Yuanquan Yang
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 10:37 PM EDT
Completed Phase 4 Interventional

A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.

NCT00293163
View directory record Official record
Conditions
Facial Wrinkles
Interventions
Hylaform, Hylaform Plus (hylan B gel)
Device
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
3
States / cities
Los Angeles, California • Warren, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 22, 2026, 10:37 PM EDT
Recruiting Phase 2 Interventional

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

NCT06406114
View directory record Official record
Conditions
Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
Interventions
Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 10:37 PM EDT
Completed No phase listed Observational Results available

Optimizing Vancomycin Therapy in Children

NCT05691309
View directory record Official record
Conditions
Sepsis, Critical Illness, Infections, Drug Toxicity
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 22, 2026, 10:37 PM EDT
Completed Not applicable Interventional

Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine

NCT00679458
View directory record Official record
Conditions
Pain
Interventions
buprenorphine and low-dose naloxone, buprenorphine alone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 22, 2026, 10:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Variable Dead Space Rebreathing Device to Treat Sleep Apnea

NCT03552133
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Sleep Apnea, Central
Interventions
Smart CO2
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 22, 2026, 10:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Calcineurin Inhibitor Sparing After Kidney Transplantation

NCT01062555
View directory record Official record
Conditions
CNI Side Effects
Interventions
Cyclosporine & Cellcept, Prograf & Cellcept, Low Dose CNI (Cyclosporine or FK) and Cellcept, Rapamune and Cellcept
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 22, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

NCT00189137
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
ifosfamide and doxorubicin vs gemcitabine and docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
10 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 22, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans

NCT01051700
View directory record Official record
Conditions
Macular Degeneration
Interventions
GW786034, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Minneapolis, Minnesota • Austin, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 22, 2026, 10:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PK of Depo SubQ Injected in the Upper Arm

NCT01143207
View directory record Official record
Conditions
Contraception
Interventions
Medroxyprogesterone acetate
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 22, 2026, 10:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study

NCT02852265
View directory record Official record
Conditions
Contraception
Interventions
Etonogestrel contraceptive implant
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
16 Years to 35 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 22, 2026, 10:37 PM EDT
Completed Phase 4 Interventional Results available

Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation

NCT00206076
View directory record Official record
Conditions
Liver Disease
Interventions
mycophenolate mofetil
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Lexington, Kentucky • Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 22, 2026, 10:37 PM EDT
Active, not recruiting No phase listed Observational

Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer

NCT05096338
View directory record Official record
Conditions
Prostate Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
Interventions
Social Determinants of Health
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 22, 2026, 10:37 PM EDT